News & Updates

As-needed application of ruxolitinib cream, a topically administered selective Janus kinase 1/2 inhibitor, resulted in long-term safety and disease control in children aged 2–11 years with mild-to-moderate atopic dermatitis (AD), according to updated results of the phase III TRuE-AD3 trial presented at EADV 2024.

Use of prescription amphetamines appears to increase the risk of incident psychosis or mania, according to a US study.

Retifanlimab takes the stage in POD1UM-303/InterAACT 2, a trial showing encouraging efficacy and favourable risk-benefit ratio when the anti-PD-1 monoclonal antibody is added to standard-of-care (SoC) chemotherapy as first-line (1L) treatment for previously untreated, inoperable, locally recurrent/metastatic squamous cell carcinoma of the anal canal (SCAC).

New drug applications approved by US FDA as of 1-15 September 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

The long-term use of skeletal muscle relaxants (SMRs) for chronic pain is beneficial only in patients with painful spasms or cramps and neck pain but not in those with low back pain, fibromyalgia, and headaches, according to the results of a systematic review and meta-analysis.